793-P: Real-World Data of Four-Year Durability of Glycemia Control with V-Go

Abstract

Patients with diabetes may struggle to comply with numerous injections required for blood glucose control. Previous studies have shown subcutaneous insulin infusion devices, such as V-Go, are an effective alternative to injections despite the limitation of the total daily dose of insulin (TDD) . The objective of this study is to validate previous work in a larger population over a longer time frame, showing V-Go significantly improves HbA1c. A retrospective analysis of patients using V-Go from 2014 to July 2020 was conducted to evaluate changes in HbA1c, TDD, weight, and number of antidiabetic medications. EMR records were obtained at a large endocrine practice in south Texas. Inclusion criteria include a DM diagnosis, baseline HbA1c within 6 weeks prior to V-Go, and at least one HbA1c 3 months after V-Go. Exclusion criteria include pregnancy and undeterminable insulin dosing. Chart review of 184 patients led to statistical evaluation of 178 patients who met criteria. As noted in Table 1, compared to baseline there was a significant decrease in HbA1c and an increase in percent of patients reaching HbA1c < 8 across measured time points. There were no significant changes to weight, TDD, or number of antidiabetics used at any time points evaluated. Our data furthers previous studies showing similar benefits to HbA1c remain significantly stable over 4 years without an increase in TDD, weight, or the average number of antidiabetic medications. Disclosure J.Vadakekalam: None. T.Copple: Employee; AstraZeneca. W.F.Trigoso: Speaker's Bureau; Amarin Corporation, Amgen Inc., Boehringer Ingelheim International GmbH, Lilly.